Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9,148 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Collaboration between the Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M™ vaccination.
Alter G, Gorman M, Patel N, Guebre-Xabier M, Zhu A, Atyeo C, Pullen K, Loos C, Goez-Gazi Y, Carrion R Jr, Tian JH, Yuan D, Bowman K, Zhou B, Maciejewski S, McGrath M, Logue J, Frieman M, Montefiori D, Schendel S, Saphire EO, Lauffenburger D, Greene A, Portnoff A, Massare M, Ellingsworth L, Glenn G, Smith G, Mann C, Amanat F, Krammer F. Alter G, et al. Among authors: patel n. Res Sq [Preprint]. 2021 Feb 15:rs.3.rs-200342. doi: 10.21203/rs.3.rs-200342/v1. Res Sq. 2021. PMID: 33619473 Free PMC article. Updated. Preprint.
Novel hemagglutinin nanoparticle influenza vaccine with Matrix-M™ adjuvant induces hemagglutination inhibition, neutralizing, and protective responses in ferrets against homologous and drifted A(H3N2) subtypes.
Smith G, Liu Y, Flyer D, Massare MJ, Zhou B, Patel N, Ellingsworth L, Lewis M, Cummings JF, Glenn G. Smith G, et al. Among authors: patel n. Vaccine. 2017 Sep 25;35(40):5366-5372. doi: 10.1016/j.vaccine.2017.08.021. Epub 2017 Aug 22. Vaccine. 2017. PMID: 28844407 Free article.
Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge.
Gilbert BE, Patel N, Lu H, Liu Y, Guebre-Xabier M, Piedra PA, Glenn G, Ellingsworth L, Smith G. Gilbert BE, et al. Among authors: patel n. Vaccine. 2018 Dec 18;36(52):8069-8078. doi: 10.1016/j.vaccine.2018.10.073. Epub 2018 Oct 30. Vaccine. 2018. PMID: 30389195
Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate.
Bangaru S, Ozorowski G, Turner HL, Antanasijevic A, Huang D, Wang X, Torres JL, Diedrich JK, Tian JH, Portnoff AD, Patel N, Massare MJ, Yates JR 3rd, Nemazee D, Paulson JC, Glenn G, Smith G, Ward AB. Bangaru S, et al. Among authors: patel n. bioRxiv [Preprint]. 2020 Aug 6:2020.08.06.234674. doi: 10.1101/2020.08.06.234674. bioRxiv. 2020. PMID: 32793901 Free PMC article. Updated. Preprint.
Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine.
Keech C, Albert G, Cho I, Robertson A, Reed P, Neal S, Plested JS, Zhu M, Cloney-Clark S, Zhou H, Smith G, Patel N, Frieman MB, Haupt RE, Logue J, McGrath M, Weston S, Piedra PA, Desai C, Callahan K, Lewis M, Price-Abbott P, Formica N, Shinde V, Fries L, Lickliter JD, Griffin P, Wilkinson B, Glenn GM. Keech C, et al. Among authors: patel n. N Engl J Med. 2020 Dec 10;383(24):2320-2332. doi: 10.1056/NEJMoa2026920. Epub 2020 Sep 2. N Engl J Med. 2020. PMID: 32877576 Free PMC article. Clinical Trial.
Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate.
Bangaru S, Ozorowski G, Turner HL, Antanasijevic A, Huang D, Wang X, Torres JL, Diedrich JK, Tian JH, Portnoff AD, Patel N, Massare MJ, Yates JR 3rd, Nemazee D, Paulson JC, Glenn G, Smith G, Ward AB. Bangaru S, et al. Among authors: patel n. Science. 2020 Nov 27;370(6520):1089-1094. doi: 10.1126/science.abe1502. Epub 2020 Oct 20. Science. 2020. PMID: 33082295 Free PMC article.
9,148 results